Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Vonjo (pacritinib citrate) is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L.
• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Pacritinib is less effective than ruxolitinib in reducing spleen volume when used as a first-line treatment for patients with myelofibrosis but shows effectiveness in second-line treatment following ruxolitinib exposure.
• Momelotinib, when used as a first-line treatment, is comparable to ruxolitinib in reducing spleen volume and total symptom score and has a positive effect on anemia, showing less toxicity on erythrocytes and platelets.
• Fedratinib demonstrates comparable efficacy to ruxolitinib in first-line therapy for spleen volume reduction in myelofibrosis patients, with slight differences in tolerance profiles that may guide therapy based on patient characteristics.
• The network meta-analysis included safety outcomes on anemia and thrombopenia events; specific safety details for pacritinib are not provided beyond its inclusion in these analyses.
• The evidence focuses on patients with myelofibrosis receiving JAK inhibitors, highlighting that pacritinib is less effective than ruxolitinib for spleen volume reduction in first-line treatment but appears effective in second-line treatment after ruxolitinib exposure; momelotinib may benefit patients with anemia and thrombopenia due to its positive effects on these conditions.